Cryoport, Inc.

Cryoport, Inc.CYRXEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Cryoport, Inc. is a global provider of specialized temperature-controlled logistics and supply chain solutions focused on the life sciences, biopharmaceutical, and cell and gene therapy sectors. It partners with research institutions, biotech firms, and pharmaceutical manufacturers globally to support the safe transport of sensitive biological materials including clinical trial samples and advanced therapy products.

Revenue

$44.2M

Gross Profit

$21.3M

Operating Profit

$-9.9M

Net Profit

$-6.9M

Gross Margin

48.2%

Operating Margin

-22.5%

Net Margin

-15.7%

YoY Growth

15.4%

EPS

$-0.18

Cryoport, Inc. Q3 FY2025 Financial Summary

Cryoport, Inc. reported revenue of $44.2M (up 15.4% YoY) for Q3 FY2025, with a net profit of $-6.9M (down 962.5% YoY) (-15.7% margin). Cost of goods sold was $22.9M, operating expenses totaled $31.3M.

Key Financial Metrics

Total Revenue$44.2M
Net Profit$-6.9M
Gross Margin48.2%
Operating Margin-22.5%
Report PeriodQ3 FY2025

Revenue Breakdown

Cryoport, Inc. Q3 FY2025 revenue of $44.2M breaks down across 3 segments, led by Products at $20.0M (45.2% of total).

SegmentRevenue% of Total
Products$20.0M45.2%
Biologistics Solutions$19.4M43.9%
Biostorage Bioservices$4.8M10.9%

Cryoport, Inc. Revenue by Segment — Quarterly Trend

Cryoport, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Biologistics Solutions) has evolved quarter over quarter.

SegmentQ4 FY2025Q3 FY2025Q2 FY2025Q1 FY2025
Products$20.0M$21.1M
Biologistics Solutions$19.4M$18.5M
Biostorage Bioservices$4.8M$4.5M$4.3M

Cryoport, Inc. Annual Revenue by Year

Cryoport, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $176.2M).

YearAnnual Revenue
2025$176.2M
2024$156.8M
2023$168.7M
2022$237.3M

Cryoport, Inc. Quarterly Revenue & Net Profit History

Cryoport, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2025$45.5M+9.6%$-8.0M-17.5%
Q3 FY2025$44.2M+15.4%$-6.9M-15.7%
Q2 FY2025$45.5M+14.5%$105.2M231.4%
Q1 FY2025$41.0M+10.1%$-12.0M-29.2%
Q4 FY2024$41.5M+665.3%$-18.7M-45.1%
Q3 FY2024$38.3M-31.8%$805.0K2.1%
Q2 FY2024$39.7M-30.4%$-78.0M-196.4%
Q1 FY2024$37.3M-40.6%$-18.9M-50.7%

Income Statement

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue$37.3M$39.7M$38.3M$41.5M$41.0M$45.5M$44.2M$45.5M
YoY Growth-40.6%-30.4%-31.8%665.3%10.1%14.5%15.4%9.6%

Balance Sheet

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Assets$942.8M$852.3M$701.8M$703.5M$699.8M$773.9M$774.3M$765.0M
Liabilities$470.7M$452.2M$283.2M$301.6M$301.0M$258.5M$261.1M$262.4M
Equity$472.2M$400.1M$418.6M$401.9M$398.8M$519.1M$513.3M$502.6M

Cash Flow

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Operating CF$-3.3M$-8.0M$447000$-5.5M$-4.3M$-7.3M$2.2M$919000